Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Non-Current Assets (2016 - 2025)

Outlook Therapeutics has reported Non-Current Assets over the past 8 years, most recently at $1.1 million for Q4 2025.

  • Quarterly Non-Current Assets fell 19.92% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Dec 2025, down 26.16% year-over-year, with the annual reading at $1.2 million for FY2025, 15.06% down from the prior year.
  • Non-Current Assets was $1.1 million for Q4 2025 at Outlook Therapeutics, down from $1.2 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $1.4 million in Q3 2024 and troughed at $1.1 million in Q4 2025.